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Background
Bradykinin (BK) plays a significant role in pathophysiol-
ogy of different diseases from angioedema to brain
stroke and heart attack by inducing vasodilatation and
increasing capillary permeability. We investigate the
potential effects of natriuretic peptides on BK signaling
by measuring membrane potential (Vm) of HEK293 cells
using the whole cell patch clamp technique. HEK293-
cells are an excellent model since they display the
natriuretic peptide receptor type A as well as both BK
receptors (BR1 and BR2).
Results
Starting Vm was -53.5 ± 1.1 mV, n = 184. To detect via-
bility of the cells hyperkalemic conditions were used
(changing K
+ from 3.6 mM to 18.6 mM) which depolar-
ized HEK293 cells by 9.7 ± 0.4 mV, n = 182. BK (100
nM) depolarized HEK293 cells by ΔVm =3 . 0±0 . 2m V ,
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Figure 1 Effects of natriuretic peptides and cGMP signaling pathway on bradykinin (BK) action. BK – bradykinin; NPPB – inhibitor of Ca
2
+-dependent Cl
- channels; ANP – atrial natriuretic peptide; URO – urodilatin; BNP – brain natriuretic peptide; CNP – C-type natiuretic peptide;
KT5823 – inhibitor protein kinase G. Number of experiments are given in brackets. * p<0.05 compared to depolarizations caused by bradykinin
alone
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BK induced depolarization by activating bradykinin
receptor type 2 (BR2) and further down the signaling
pathway activation of Ca
2+-dependent Cl
- channels (Fig-
ure 1).
Natriuretic peptides display different effects on the
BK-induced depolarization due to activation of Ca
2
+-dependent Cl
--channels. While ANP, urodilatin, BNP
(all acting though guanylate cyclase A) and 8-Br cGMP
inhibited the BK-induced depolarization, CNP (acting
through guanylate cyclase B) failed to do so (Figure 1).
Effects of urodilatin on BK-induced deoplarization could
be reversed by inhibiting protein kinase G (using the
specific inhibitor KT5823) suggesting an inhibitory role
of natriuretic peptides via GC-A, cGMP and PKG in BK
signaling.
Conclusion
From our results we could speculate that natriuretic
peptides might display beneficial effects in different
pathological conditions caused by BK.
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